Structure, Vol. 12, 477-486, March, 2004, ©2004 Elsevier Science Ltd. All rights reserved. DOI 10.1016/j.str.2004.02.006

ADP-Ribosyl Cyclase: Crystal Structures Reveal a Covalent Intermediate

Michael L. Love,¹ Doletha M.E. Szebenyi,¹ Irina A. Kriksunov,¹ Daniel J. Thiel,¹ Cyrus Munshi,² Richard Graeff,² Hon Cheung Lee,^{2,*} and Quan Hao^{1,*} ¹Molecular Biology and Genetics Cornell University Ithaca, New York 14853 ²Department of Pharmacology University of Minnesota Minneapolis, Minnesota 55455

Summary

ADP-ribosyl cyclase catalyzes the elimination of nicotinamide from NAD and cyclization to cADPR, a known second messenger in cellular calcium signaling pathways. We have determined to 2.0 Å resolution the structure of Aplysia cyclase with ribose-5-phosphate bound covalently at C3' and with the base exchange substrate (BES), pyridylcarbinol, bound to the active site. In addition, further refinement at 2.4 Å resolution of the structure of nicotinamide-bound cyclase, which was previously reported, reveals that ribose-5-phosphate is also covalently bound in this structure, and a second nicotinamide site was identified. The structures of native and mutant Glu179Ala cyclase were also solved to 1.7 and 2.0 Å respectively. It is proposed that the second nicotinamide site serves to promote cyclization by clearing the active site of the nicotinamide byproduct. Moreover, a ribosylation mechanism can be proposed in which the cyclization reaction proceeds through a covalently bound intermediate.

Introduction

ADP-ribosyl cyclase catalyzes the elimination of nicotinamide from NAD and the production of second messenger cADPR (Lee et al., 1994 and reviewed in Lee, 2001). cGMP-activated kinase can stimulate the cyclase activity (Willmott et al., 1996), which is essential to the process of calcium-induced calcium release (CICR), a key component of the calcium signaling mechanism which controls cellular development. The propagation of this calcium signal component has been studied in sea urchin egg preparations (Lee 1991, 1996; Lee et al., 1995), and cyclase has been implicated in CICR potentiation (Lee et al., 1993, 1995). The enzyme is a 29 kDa protein and crystallizes as a functionally relevant dimer (Prasad et al., 1996), and is similar to BST-1, a cell surface antigen which has been implicated in severe rheumatoid arthritis (Kaisho et al., 1994; Dong et al., 1994; Itoh et al., 1994; Yamamoto-Katayama et al., 2002). The cyclase dimer is a model for surface antigen CD38, which may play a role in various immune system functions (States et al., 1992; Jackson and Bell, 1990; Harada et al., 1993; Koguma et al., 1994; Li et al., 1994). CD38 and ADP- ribosyl cyclase catalyze similar reactions, and the amino acid sequences are 30% identical. In the dimer, the substrate binding grooves are turned inward toward a central channel or cavity so that they are somewhat hidden from the solvent. It has been suggested that a channel, which is formed in the dimer, provides access to the catalytic core for substrates. The channel is large enough for products and reagents, as well as water and various ions, so it is unlikely that hydrolysis of intermediates is blocked by the constraints of the channel space topology. Moreover, channel access would of course be required for mechanism-based inhibitors which have been shown to block cyclization in CD38 (Sauve and Schramm, 2002).

Here we report the crystallographic structures of ADPribosyl cyclase covalently bound to C3' of ribose-5phosphate (R5P), in complex with pyridylcarbinol and nicotinamide respectively. In addition, the native cyclase structure was determined to 1.7 Å resolution, which is the highest resolution to date for the cyclase family, and the structure of the Glu179Ala cyclase mutant was also solved. The kinetic competence of cyclase to hydrolyze nicotinamide mononucleotide to R5P and nicotinamide was demonstrated by HPLC analysis. Based on a structural overlay of conserved residues, it appears that the overall topology of the dimer protects the substrate binding surfaces from proteolysis and blocks nonspecific access to the active site. In contrast to structures which were previously reported (Prasad et al., 1996; Yamamoto-Katayama et al., 2002), the R5P ribose ring is covalently linked to Glu179, the so-called catalytic residue of the BES-bound structures, so that the interaction of ribose-5-phosphate with a site adjacent to the pyridylcarbinol and nicotinamide site is revealed, and an enzymatic mechanism can be proposed which includes a covalent intermediate.

Results and Discussion

Overview of the Structure

The structures of ADP-ribosyl cyclase with bound pyridylcarbinol or nicotinamide BES (Munshi et al., 1999) are highly similar to those of mutant and native cyclase, except that no reagents were bound to the active site in either the mutant or native case. Although the 1.7 Å resolution structure was obtained from crystals grown in the presence of NGD, no bound substrate was found, and this structure is considered as native cyclase. In the case of the BES-bound structures, cyclization substrate reagents were not added to the crystallization mixture, so that the bound substrate or R5P was apparently copurified with the protein; in the absence of nicotinamide or pyridylcarbinol, the R5P was apparently hydrolyzed away. A similar effect has been observed with the NAD+dependent deacetylase enzyme, SIR2: BES favors the accumulation of a covalent intermediate (Sauve and Schramm, 2003). The current structures are all similar to the first crystallographic structure of cyclase (Prasad



atmust			d	imer int.		раск	ing		- Tm77		-			nackin
struct	1	10	20	30	40	50	60	70	80	90	100	110	120	130
ai 11277941 en 18292411	TUPTPEL	ENVEL CE					I GSYKDEET		HEUSCUYNEOU	VONTOPRYT			COPONPOE	
gi 12d93d271en1027312	TVPTREI	ENVEL GE	CKNYFTTRY	NTI PRVRSNC		RESEKNPCOLD	GSYKDEFT	SADOOL PKNKV	FUSGVYDEAH	YANTGREYT	TI EDTI PG	YHI NSI VUC	GORANPGE	EKVCPDE-K
gi125547611pdb11LBE1	IFPTPEL	ONVELGE	CKDYEITRYL	TILPRYKSDC	RALHINFEK	FSFKAPCNLD	LGSYKDFFO	RADOTLPKNKY	FHSGYYDEAHD	FADDGRKYI	TLEDTLPG	YHLNSL YHC	GORDKPGF	OKYCPDF-K
gi1201502831pdb11ISI	GTSAHL	RDIFLGR	RCAEYRALL	SPEQR-NKDC	TATHEAFKY	-LDKDPCSYL	PSDYDLFIT	LSRHSIPRDKS	LFHENSHLLVNS	FADNTRRFH	PLSDVLYG	RYADFLSHC	ROKADSGL	DYOSCPT-SE
gil150823651gb1AAH12	GTSAHL	RDIFLGR	RCAEYRALL	SPEQR-NKNC	TATHEAFKY	H-LOKOPCSYL	PSDYDLFIN	LSRHSIPROKS	LFHENSHLLYNS	FADNTRRFM	PLSDYLYG	RYADFLSHC	ROKNDSGL	DYQSCPT-SE
gil47578741refINP_00	GTSAHL	RDIFLGR	RCAEYRALL	SPEQR-NKNC	TAIHEAFKY	A-LOKOPCSYL	PSDYDLFIN	LSRHSIPROKS	LFHENSHLLYNS	FADNTRRFM	PLSDYLYG	RYADFLSHC	ROKNDSGL	DYQSCPT-SE
gil67532021ref1NP_03	GTTPHL	QSIFLG	RCAEYTTLL	SLG-NKNC	TAIHEAFKG	-LDKDPCSYL	PSDYDLFIN	LSRHPIPRDKS	LFHENNHLLYMS	SYGENTRRLY	ALCOYLYG	KYGDFLSHC	ROENASGL	DYQSCPT-SE
gil208303541ref1XP_1	GTTPHL	QSIFLG	RCAEYTTLL	SLG-NKNC	TATHEAFKG	-LDKDPCSYL	PSDYDLFIN	LSRHPIPRDKS	LFHENNHLLYMS	SYGENTRRLY	ALCOVLYG	KYGDFLSHC	ROENASGL	DYQSCPT-SE
gil135406581refINP_1	GITPHL	USIFLE	CHEYITLL	SLEPG-NKNC	THINEH-KY	-LOKOPCSYL	PSUYULFIN	LSRHHIPRUKS	LEHENNHLLYMS	THENTRRLM	PLCOVLYG	KYGDELSHC	RUENHSGL	JYUSCPT-HE
g1166808821ret INP_03	PIKHF	SUTL CO	CLIT IUIL	KPERK-DUNL	QETLST KU	HEYSKNPLNII	REDTHPLYK	LYIUIIPLNKI	LFH5K5KHLHH	THIUGKNE	TLEDILLO	TINUULKHU	CODCTCDM	TYSLPHASE
g11208303611Fet IAP_1	PTTVUE	SUIPLUM		RPERK-DUNC	VEILST KU	TELEVIDENT		LYIQIIPUNKI		TUTOCKHE	TI COTLLO	TIMUULKHU	COPCTON	VDCCDUUCE
g1103/00231101 INF_03	CTTONE	VETILO	CYTY-TOWN		OFTER TO	DEL CKUDCCCT		TTOTYPONET	VEUCYCCEI OUR		TI EDTLLG	AHOUCI KHC	COTCCCCM	VOCCOULDE
ail136467541cef1XP 0	GATDHY	SATVIGE	CI TYTRNH	HPFI R-NODC	KKTI NTETS	REVSKOPCOT		UTOTVPCNKT	FUSRSKEL AHO	YSGTOKENE	TI FBTI I G	YTANNI VUC	GOPRISEV	EFECPYENE
gild5026651refINP_00	GATDHY	SATVI GR	CI TYTRNM	HPFI R-NODC	KKTI NTETS	REVSKOPCNTT	KENYOPI TO	VTOTVPCNKT	FUSRSKEL AHO	YSGTOKENE	TI EDTLI G	YTANNI VHC	GOPRESEV	EFECPYENE
gi1212634601sp109M20	GTTKRF	PETYLAR	CYKYTE-I	HPEMR-HYDC	OSYHDAFKG	FISKHPCNIT	EEDYOPLHK	LGTOTYPCNKI	LHSRTKDLAH	FTOYORDHE	TLEDTLLG	YLADDI THC	GEENTSKI	YOSCPDHRK
ei1113603401pir11JC7	GTTKRF	PETYLAR	CYKYTE-I	HPEMR-HYDC	OSYHDAFKG	REISKHPCNIT	EEDYOPLHK	LGTOTYPCNKI	LHSRIKDLAHO	FTOYORDHF	TLEDTLLG	YLADDLTHC	GEFNTSKI	YOSCPDHRK
Consensus	.gtt.h.	ifLg	RCYL1	.pe.R#C		af.sK.PCn.t	dY.pl	1.tqt.Pc#K.	fHs.slah.	%qr.n.	tLeDtL16	y.a#.L.HC	g s	ny.sCPe
					-	Gh	179-		-pag	king-	dimer i	nLa	-	- packing -
	131	140	150	160	170	180	190	200	210	220	230	240	250	260
	131 	140	150	160	170	180	190	200	210	220	230	240	250	260
gi 127794 sp P29241	131 I TCPVQAR	ESFHGHR	150	160 EVTYMVDGSN	170	180	190	200	210 IEKCGAGSLLDI	220 EKLVKAKHF	230	240	250	260 I RLAKRFYRIA
gil127794 sp P29241 gil2493427 sp Q27312 cil2554761 odb 1 BE	131 I TCPVQAR TCPVQAR	ESFHGHF ESFHGHF	150 SSSYAHSAEG	160 EVTYHVDGSN EVTYHVDGSN DVTYHVDGSN	170 PKVPAYRPD PKVPAYRPD		190 -TNKYTRYK -TNKYTRYK -TNKYTRYK	200 VIVLHRLGEKI VIVLHRLGEKI	210 IEKCGAGSLLD IEKCGAGSLLD	220 EKLVKAKHF EKLVKAKHF	230 AFDCVENP AFDCVENP GEDCVENP	240 RRVLFLLCS RAVLFLLCS	250 DNPNARECI DNPNARECI	260 1 RLAKRFYRIA RLAKRFYRIA
gi 127794 sp P29241 gi 2493427 sp Q27312 gi 2554761 pdb 1LBE ci 201502831odb 1151	131 I TCPVQAR TCPVQAR DCPVQAR	140 ESFNGMF ESFNGMF ESFNGTF	150 SSSYAHSAEG SSSYAHSAEG SSSYAHSAEG	160 EVTYHVDGSN EVTYHVDGSN DVTYHVDGSN VTHVHLNGSE	170 PKVPAYRPD PKVPAYRPD PKVPAYRPD PKVPAYRPD PT-GAYPTK	180 SFFGKYELPNL SFFGKYELPNL SFFGKYELPNL SFFGMYETPNL	190 -TNKYTRVK -TNKYTRVK -TNKYTRVK OKEKTTRTE	200 VIVLHRLGEKI VIVLHRLGEKI VIVLHQLGQKI VIVLHQLGQKI	210 IEKCGAGSLLD IEKCGAGSLLD IERCGAGSLLD VESTGEGSMKV	220 EKLVKAKHF EKLVKAKHF EMVVKAKKF EKRI KDMGE	230 AFDCVENP AFDCVENP GFDCVENP OVSCTNDV	240 RAVLFLLCS RAVLFLLCS KSVLFLLCA	250 DNPNAREC DNPNAREC DNPNAREC DNPNAREC	260 1 RLAKRFYRIA RLAKRFYRIA QLAKRYYRIA ALKSAAAATO
gi 127794 sp P29241 gi 2493427 sp Q27312 gi 2554761 pdb 11.BE gi 20150283 pdb 11.ST ei 15082365 pdb 11.ST	131 I TCPVQAR TCPVQAR DCPVQAR DCENNPV DCENNPV	140 ESFNGMF ESFNGMF ESFNGTF DSFNKRF	150 SSSYAHSAEG SSSYAHSAEG SSSYAHSAEG SSSYAHSAEG SSYAHSAEG SSYAHSAEG	160 EVTYHVDGSN EVTYHVDGSN DVTYHVDGSN VIHVHLNGSE VIHVHLNGSE	170 PKVPAYRPD PKVPAYRPD PKVPAYRPD PT-GAYPIK PT-GAYPIK	180 SFFGKYELPNL SFFGKYELPNL SFFGKYELPNL SFFADYEIPNL SFFADYEIPNL	190 -TNKYTRYK -TNKYTRYK -TNKYTRYK QKEKITRIE QKEKITRIE	200 VIVLHRLGEKT VIVLHRLGEKT VIVLHQLGQKT INVHHETGGPN THVHHETGGPN	210 IEKCGAGSLLD IEKCGAGSLLD IERCGAGSLLD VESCGEGSMKV VESCGEGSMKV	220 EKLVKAKHF EKLVKAKHF EMVVKAKKF EKRLKDMGF EKRLKDMGF	230 AFDCVENP AFDCVENP GFDCVENP QYSCINDY DYSCINDY	240 RAVLFLLCS RAVLFLLCS KSVLFLLCA RPVKLLQCV RPVKLLQCV	250 DNPNAREC DNPNAREC DNPNAREC DNPNAREC DNSTHPDC /DHSTHPDC	260 I RLAKRFYRIA RLAKRFYRIA RLAKRYYRIA ALKSAAAATQ ALKSAAAATQ ALKSAAAATQ
gi 127794 sp P29241 gi 2493427 sp Q27312 gi 2554761 pdb 11.BE gi 201502831 pdb 11.SI gi 15082365 gb AAH12 si 4757874 ref NP_00	131 I TCPYQAR TCPYQAR DCPYQAR DCENNPY DCENNPY DCENNPY	140 ESFNGMF ESFNGMF ESFNGTF DSFNKRF DSFNKRF	150 SSSYAHSAEG SSSYAEG SSSYAHSAEG SSSYAHSAEG SSSYAHSAEG SSSYAEG SSSYAEG SSSYAEG SSSYABSAEG SSSYAEG SSYAEG SSSYAEG SSYAEG	160 EVTYHVDGSN EVTYHVDGSN DVTYHVDGSN VIHVHLNGSE VIHVHLNGSE VIHVHLNGSE	170 PKVPAYRPD PKVPAYRPD PKVPAYRPD PT-GAYPIK PT-GAYPIK PT-GAYPIK	180 SFFGKYELPNL SFFGKYELPNL SFFGKYELPNL GFFADYEIPNL GFFADYEIPNL	190 -TNKYTRYK -TNKYTRYK -TNKYTRYK QKEKITRIE QKEKITRIE QKEKITRIE	200 VIVLHRLGEKI VIVLHRLGEKI VIVLHQLGQKI INVHHEIGGPN INVHHEIGGPN	210 IEKCGAGSLLDI IEKCGAGSLLDI IERCGAGSLLDI VESCGEGSMKVI VESCGEGSMKVI VESCGEGSMKVI	220 EKL VKAKHF EKL VKAKHF EKRLKDMGF EKRLKDMGF EKRLKDMGF	230 AFDCVENP AFDCVENP GFDCVENP QYSCINDY QYSCINDY QYSCINDY	240 RAVLFLLCS RAVLFLLCS KSVLFLLCA RPVKLLQCV RPVKLLQCV RPVKLLQCV	250 DNPNAREC DNPNAREC DNPNAREC DNSTHPDC DHSTHPDC DHSTHPDC	260 I RLAKRFYRIA RLAKRFYRIA ALKSAAAATQ ALKSAAAATQ ALKSAAAATQ ALKSAAAATQ
gi 1277941 sp 1 P292411 gi 124934271 sp 1 Q27312 gi 12554761 1 pd 1 1 BE 1 gi 1201502831 pd 1 1 TST gi 1 150823651 gb 1 ARH12 gi 1 47578741 ref 1 NP_00 gi 1 67532021 ref 1 NP_03	131 I TCPVQAR TCPVQAR DCPVQAR DCENNPV DCENNPV DCENNPV DCENNAV	140 ESF HGHF ESF HGHF ESF HGTF DSF HKRF DSF HKRF DSF HKRF DSF HKRF	150 SSSYAHSAEG SSSYAHSAEG SSSYAHSAEG SSQYSKDSSG SSQYSKDSSG SSQYSKDSSG SSQYSKDSSG	160 EVTYHVDGSN EVTYHVDGSN DVTYHVDGSN VIHVHLNGSE VIHVHLNGSE VIHVHLNGSE VINVHLNGSE	170 PKVPAYRPD PKVPAYRPD PKVPAYRPD PT-GAYPIK PT-GAYPIK PT-GAYPIK PK-GAYPIR	180 SFFGKYELPNL SFFGKYELPNL GFFADYEIPNL GFFADYEIPNL GFFADYEIPNL GFFADYEIPNL	190 -TNKYTRYK -TNKYTRYK -TNKYTRYK QKEKITRIE QKEKITRIE QKEKITRIE QKDKYTRIE	200 VIVLHRLGEKI VIVLHRLGEKI IVVHRLGEKI INVHHEIGGPN INVHHEIGGPN INVHHEIGGPN INVHHEIGGPN	210 IEKCGAGSLLDI IEKCGAGSLLDI IERCGAGSLLDI VESCGEGSHKVI VESCGEGSHKVI VESCGEGSHKVI VESCGEGSHKVI	220 EKL VKAKHF EKL VKAKHF EKRLKDMGF EKRLKDMGF EKRLKDMGF EDRLEALGF	230 AFDCVENP AFDCVENP GFDCVENP QYSCINDY QYSCINDY QYSCINDY QHSCINDY	240 RAVLFLLCS RAVLFLLCS KSVLFLLCA RPVKLLQCV RPVKLLQCV RPVKLLQCV RPVKLLQCV	250 DNPNAREC DNPNAREC DNPNAREC DNSTHPDC DHSTHPDC DHSTHPDC DHSTHPDC	260 I RLAKRFYRIA RLAKRFYRIA RLAKRYYRIA ALKSAAAATQ ALKSAAAATQ ALKSAAAATQ ILKSAAAATQ ILKSAAAATQ ILKSAASHR
gil277941splP292411 gil24334271splQ27312 gil2554761pdb111E1 gil20502831pdb111S1 gil20502851gb1AH51 gil20502651gb1AH500 gil67532021ref1NP_00 gil208302541ref1NP_1	131 I TCPYQAR TCPYQAR DCPYQAR DCENNPY DCENNPY DCENNPY DCENNAY	140 ESF HGMF ESF HGMF DSF HKRF DSF HKRF DSF HKRF DSF HKRF DSF HKRF DSF HKRF	150 SSSYAHSAEG SSSYAHSAEG SSSYAHSAEG SSQYSKDSSG SSQYSKDSSG SSQYSKDSSG SSQYSKDSSG SSQYSKDSSG	160 EVTYHVDGSN EVTYHVDGSN DVTYHVDGSN VIHVHLNGSE VIHVHLNGSE VIHVHLNGSE VINVHLNGSE VINVHLNGSE	170 PKVPAYRPD PKVPAYRPD PT-GAYPIK PT-GAYPIK PT-GAYPIK PK-GAYPIR PK-GAYPIR	180 FFGKYELPNL SFFGKYELPNL SFFGKYELPNL GFFADYEIPNL GFFADYEIPNL SFFADYEIPYL SFFADFEIPYL	190 -TNKVTRVK -TNKVTRVK QKEKITRIE QKEKITRIE QKEKITRIE QKDKVTRIE	200 VIVLHRLGEKI VIVLHRLGEKI VIVLHRLGEKI VIVLHRLGGRM INVHHEIGGPM INVHHVGGPN INVHHVGGPN INVHHVGGPN	210 IEKCGAGSLLDI IERCGAGSLLDI VESCGEGSHKVI VESCGEGSHKVI VESCGEGSHKVI VESCGEGSVKTI VESCGEGSVKTI	220 EKL VKAKHF EKL VKAKHF EKRLKDMGF EKRLKDMGF EKRLKDMGF EDRLEALGF EDRLEALGF	230 AFDCVENP AFDCVENP GFDCVENP QYSCINDY QYSCINDY QYSCINDY QHSCINDY QHSCINDY	240 RAVLFLLCS RAVLFLLCS KSVLFLLCA RPVKLLQCV RPVKLLQCV RPVKLLQCV RPVKFLMCV RPVKFLMCV	250 CONPNAREC CONPNAREC CONPNAREC CONSTHPDC CONSTHPDC CONSTHPDC CONSTHPDC CONSTHPDC	260 I RLAKRFYRIA RLAKRFYRIA RLAKRFYRIA RLAKSAAAATQ RLAKSAAAATQ RLKSAAAATQ RLKSAAAATQ ILNSASASMR INNSASSMR INNSASSMR
eil1277941ep1P292411 eil24934271ep1Q27312 gil25547611pdb11LBE1 gil201502831pdb11LBE1 gil150023651gb1RH112 gil47578741ref1NP_03 gil67532021ref1NP_03 gil208303541ref1NP_03	131 I TCPYQAR TCPYQAR DCENNPY DCENNPY DCENNPY DCENNAY DCENNAY	140 ESF HGMF ESF HGMF DSF HKRF DSF HKRF DSF HKRF DSF HKRF DSF HKRF DSF HKRF DSF HKRF DSF HKRF	150 SSSYAHSAEG SSSYAEG SSSYAHSAEG SSSYAHSAEG SSSYAHSAEG SSSYAHSAEG SSSY	160 EVTYHYDGSN EVTYHYDGSN DVTYHYDGSN VIHYHLNGSE VIHYHLNGSE VIHYHLNGSE VINYHLNGSE VINYHLNGSE VINYHLNGSE	170 PKVPAYRPD PKVPAYRPD PKVPAYRPD PT-GAYPIK PT-GAYPIK PK-GAYPTR PK-GAYPTR PK-GAYPTK	180 FFGKYELPNL FFGKYELPNL FFGKYELPNL FFADYEIPNL FFADYEIPNL FFADFEIPYL FFADFEIPYL FFADFEIPYL	190 -TNKVTRVK -TNKVTRVK -TNKVTRVK QKEKITRIE QKEKITRIE QKOKVTRIE QKOKVTRIE QKOKITRIE	200 YIVLHRLGEKI YIVLHRLGEKI YIVLHQLGQKI IHVHHEIGGPM IHVHHEIGGPM IHVHHDVGGPM IHVHHDVGGPM IHVHHDVGGPM IHVHHEVGGPM	210 IEKCGAGSLLDI IERCGAGSLLDI VESCGEGSHKVI VESCGEGSHKVI VESCGEGSVKII VESCGEGSVKII VESCGEGSVKII	220 EKL VKAKHF EKL VKAKKF EKRLKDMGF EKRLKDMGF EKRLKDMGF EDRLEALGF EDRLEALGF EDRLEALGF	230 AFDCVENP AFDCVENP QFDCVENP QVSCINDY QVSCINDY QHSCINDY QHSCINDY QHSCINDY	240 RAVLFLLCS RAVLFLLCS KSVLFLLCA RPVKLLQCV RPVKLLQCV RPVKFLHCV RPVKFLHCV PPVKFLHCV	250 CONPNARECI CONPNARECI CONSTHPDCI CONSTHPDCI CONSTHPDCI CONSTHPDCI CONSTHPDCI CONSTHPDCI CONSTHPDCI	260 I AKRFYRIA LAKRFYRIA LAKRYYRIA LAKRYYRIA LKSAAAATQ ILKSAAAATQ ILKSAAAATQ ILKSAAAATQ ILKSAASATR ILKSAASATR IINSASSTH
gi 1277941 sp 1292411 gi 12493427 sp 1027182 gi 12534761 lpd 111851 gi 12504761 lpd 111517 gi 1150023651 gb 10AH12 gi 1150023651 gb 10AH12 gi 1257874741 ref 1MP_00 gi 1208303541 ref 1MP_1 gi 125406581 ref 1MP_13 gi 165808821 ref 1MP_13	131 I CPYQAR TCPYQAR DCPYQAR DCPNAPY DCENNAY DCENNAY DCENNAY DCENNAY DCENNAY NCPNNPI	140 ESF AGME ESF AGME ESF AGME DSF AKRE DSF AKRE DSF AKRE DSY AKSE DSY AKSE DSY AKSE DSY AKSE DSY AKSE DSY AKSE DSY AKSE	150 SSSYAHSAEG SSSYAHSAEG SSSYAHSAEG SSYAHSAEG SSYAKSSG SSTQYSKDSSG SSTQYSKDSSG SHQYSRDSSG SHQYSRDSSG SSHQYSRDSSG SSHQYSRDSSG SSHQYSRDSSG	160 EVTYMVDGSN EVTYMVDGSN DVTYMVDGSN UTYMVDGSN VINVMLNGSE VINVMLNGSE VINVMLNGSE VINVMLNGSE VINVMLNGSE	170 PKVPAYRPO PKVPAYRPO PT-GAYPIK PT-GAYPIK PK-GAYPIK PK-GAYPTK REPFYKN	180 FFGKYELPNL FFGKYELPNL FFGKYELPNL FFGKYELPNL FFADYEIPNL FFADFEIPYL FFADFEIPYL FFFADFEIPYL SFFGSLEVFSL	190 	200 VIVLHRLGEKI VIVLHRLGEKI VIVLHQLGQKI INVHHEIGGPN INVHHEIGGPN INVHHDVGGPN INVHHEVGGPH ANVHDIEGAS	210 IEKCGAGSLLDI IEKCGAGSLLDI IERCGAGSLLDI VESCGEGSHKVI VESCGEGSHKVI VESCGEGSVKII VESCGEGSVKII SNACSSSSLNEI	220 EKL VKAKHF EKL VKAKHF EKRLKDMGF EKRLKDMGF EKRLKDMGF EDRLEALGF EDRLEALGF EDRLEALGF KHTVQKRNM	230 AFDCVENP AFDCVENP QFDCVENP QYSCINDY QYSCINDY QHSCINDY QHSCINDY QHSCINDY QHSCINDY QHSCINDY	240 RAVLFLLCS KSVLFLLCS RVVLLLCV RPVKLLQCV RPVKLLQCV RPVKFLHCV RPVKFLHCV RPVKFLHCV RPARFLQCV	250 COMPNARECI COMPNARECI COMPNARECI COMSTHPDCI C	260 2
gi 1277941 spi P292411 gi 124934271 spi 027312 gi 12954761 jedb 11.0E i gi 12015023051 jedb 11.3E gi 14578741 ref 1MP_00 gi 1208303541 ref 1XP_10 gi 1208303541 ref 1XP_11 gi 155808821 ref 1MP_03 gi 120830351 ref 1XP_11 gi 165808821 ref 1MP_03	131 I TCPYQAR TCPYQAR DCPYQAR DCENNPY DCENNPY DCENNPY DCENNAY DCENNAY NCPNNPI NCPNNPI	140 ESF IGHE ESF IGHE DSF IKRE DSF IKRE DSF IKRE DSY IKSE DSY IKSE DSY IKSE DSY IKSE DSY IKSE DSY IKSE DSY IKSE THF IKY I	150 SSYAHSAEG SSYAHSAEG SSYAHSAEG SIQYSKDSSG SIQYSKDSSG SHQYSRDSSG SHQYSRDSSG SHQYSRDSSG SHQYSRDSSG SHQYSRDSSG SHQYSRDSSG SHQYSRDSSG SHQYSRDSSG SHQYSRDSSG	160 EVTYHVDGSN EVTYHVDGSN DVTYHVDGSN VIHVHLNGSE VIHVHLNGSE VINVHLNGSE VINVHLNGSE VINVHLNGSE VVQVHLNGSL	170 PKVPAYRPD PKVPAYRPD PKVPAYRPD PT-GAYPIK PT-GAYPIK PK-GAYPTR PK-GAYPTR PK-GAYPTR REPFYKN REPFYKN	180 SFFGKYELPNL SFFGKYELPNL SFFGKYELPNL SFFGDYEIPNL SFFADFEIPYL SFFADFEIPYL SFFADFEIPYL SFFADFEIPYL SFFADFEIPYL SFFGSVEVFSL	190 	200 VIVLHRLGEKI VIVLHRLGEKI VIVLHQLGQKI INVHHEIGGPN INVHHEIGGPN INVHHVGGPN INVHHVGGPN INVHHEVGGPN INVHHEGGSS	210 IEKCGAGSLLDI IEKCGAGSLLDI IEKCGAGSLLDI VESCEGSHKVI VESCEGSHKVI VESCEGSHKVI VESCEGSVKII VESCEGSVKII VESCEGSVKII SNACSSSSLNEI	220 EKL VKRKHF EKL VKRKF EKL KDNGF EKRL KDNGF EKRL KDNGF EDRL EAL GF EDRL EAL GF EDRL EAL GF EDRL EAL GF EDRL EAL GF EDRL EAL GF KNI VQKRNM	230 AFDCVENP AFDCVENP QFDCVENP QYSCINDY QYSCINDY QHSCINDY QHSCINDY IFACVDNY	240 RAVLFLLCS RAVLFLLCS KSVLFLLCA RPVKLLQCV RPVKLLQCV RPVKLLQCV RPVKFLHCV PPVKFLHCV RPARFLQCV	250 COMPNARECI COMPNARECI COMSTHPDCI COHSTHPDCI COHSTHPDCI COHSTHPDCI COHSTHPDCI COHSTHPDCI XMPEHPSCI XMPEHPSCI	260
gi 1277941 sp 1292411 gi 124934271 sp 1027312 gi 12554761 lpdb 11LEE l gi 120150823651 gb 1AM112 gi 120150823651 gb 1AM112 gi 14757824021 ref 1MP_00 gi 167532021 ref 1MP_10 gi 120830361 ref 1MP_10 gi 165080821 ref 1MP_10 gi 165080821 ref 1MP_10	131 I TCPVQAR DCPVQAR DCENNPY DCENNPY DCENNPY DCENNAY DCENNAY NCPNNPI NCPNNPI	140 ESF HGHF ESF HGHF ESF HGHF DSF HKRF DSF HKRF DSF HKRF DSF HKRF DSY HKSF DAYHKSF DAYHKSF THF HKYI TYF HKYI	150 ISSSYAHSAEG ISSSYAHSAEG ISSSYAHSAEG ISSSYAHSAEG ISSSYAHSAEG ISSSYAHSAEG ISSSYAHSAEG ISSSSS ISSSSS ISSSSS ISSSSS ISSSSS ISSSSS ISSSSS ISSSSS ISSSSS ISSSSS ISSSSS ISSSSS ISSSSS ISSSSS ISSSSS ISSSS ISSSS ISSSS ISSSS ISSSS ISSSS ISSSS ISSSS ISSSS ISSSS ISSSS ISSSS ISSSS ISSSS ISSSS ISSSS ISSSS ISSSS IS I	160 EVTYHVDGSN EVTYHVDGSN DVTYHVDGSN DVTHVLNGSE VIHVHLNGSE VIHVHLNGSE VINVHLNGSE VINVHLNGSE VVQVHLNGSL VVQVHLNGSL	170 PKVPAYRPD PKVPAYRPD PKVPAYRPD PT-GAYPIK PT-GAYPIK PK-GAYPTR PK-GAYPTR PK-GAYPTR REPFYKN REPFYKN	180 FFFGKYELPNL FFFGKYELPNL FFFGYELPNL FFROYEIPNL FFROFEIPYL FFROFEIPYL FFROFEIPYL SFFGOFEIPYL SFFGOFEIPYL SFFGSEVFSL SFFGSVEVFSL	190 - TNKVTRVK - TNKVTRVK - TNKVTRVK QKEKITRIE QKEKITRIE QKOKVTRIE QKOKVTRIE QKOKVTRIE DPNKVHKLQ DPNKVHKLQ	200 VIVLIRLGEKT VIVLIRLGEKT VIVLIRLGEKT VIVLIRLGERT INVIHEIGGPN INVIHEIGGPN INVIHEIGGPN INVIHEIGGPN INVIHEIGGPN INVIHEIGGPN ANVIHDIEGAS ANVIHDIEGAS	210 TEKCGAGSLLDI TEKCGAGSLLDI TERCGAGSLLDI TERCGAGSLLDI VESCGEGSMKVI VESCGEGSMKVI VESCGEGSWKTI SNACSSSSLNEI SNACSSSSLNEI SNACSSSSLNEI	220 EKL VKAKHF EKL VKAKHF EKL KONGF EKRL KONGF EKRL KONGF EDRL EALGF EDRL EALGF EDRL EALGF EDRL EALGF KNI VQKRNM KNI VQKRNM KSI VNKRNM	230 AFDCVENP AFDCVENP QFDCVENP QYSCINDY QYSCINDY QHSCINDY QHSCINDY IFACVDNY IFACVDNY IFACQDNY	240 RRVLFLLCS RSVLFLLCS KSVLFLLCR RPVKLLQCV RPVKLLQCV RPVKFLHCV RPVKFLHCV RPVKFLHCV RPARFLQCV RPARFLQCV	250 CONPNARECI CONPNARECI CONSTHPDCI CONSTHPDCI CONSTHPDCI CONSTHPDCI CONSTHPDCI CONSTHPDCI CONSTHPDCI KNPEHPSCI KNPEHPSCI	260 200 200 200 200 200 200 200
: gi 1277941 spi P292411 gi 124934271 spi 027312 gi 12554761 hedb 11.0E1 gi 12554761 hedb 11.0E1 gi 12015023651 gb 148412 gi 147578741 ref 110-03 gi 120803621 ref 110-03 gi 120803621 ref 110-13 gi 120804581 ref 110-13 gi 1	131 I — TCPVQAR TCPVQAR DCPVQAR DCENNPY DCENNPY DCENNAY DCENNAY DCENNAY NCPNNPI NCPNNPI NCPNNPY	140 ESF HGHF ESF HGHF DSF HKRF DSF HKRF DSF HKRF DSF HKRF DSY HKSF DAY HKSF DAY HKSF THF HKVI TYF HKVI SYF HNYI SYF HNYI	150 555YAHSAEG 555YAHSAEG 555YAHSAEG 555YAHSAEG 550YSKDSSG 550YSKDSSG 540YSRDSSG 540YSRDSSG 540YSRDSSG 540YSRDSSG 540YSRDSSG 50KFAEDACG 50KFAEDACG 50KFAEDACG	160 EVTYHVDGSN EVTYHVDGSN DVTYHVDGSN VIHVHLNGSE VIHVHLNGSE VIHVHLNGSE VINVHLNGSE VVQVHLNGSL VVQVHLNGSL VVQVHLNGSL VVQVHLNGSL	170 PKVPAYRPD PKVPAYRPD PT-GAYPIK PT-GAYPIK PK-GAYPTR PK-GAYPTR PK-GAYPTR REPFYKN SEPFYKN SNTFDEK	180 FFFGKYELPNL FFFGKYELPNL FFFGKYELPNL FFFGVEIPNL FFFADFEIPYL FFADFEIPYL FFADFEIPYL FFADFEIPYL SFFADFEIPYL SFFGSLEVFSL STFGSVEVFSL STFGSVEVFL STFGSVEVFNL	190 -TNKVTRVK -TNKVTRVK -TNKVTRVK QKEKITRIE QKEKITRIE QKOKYTRIE QKOKITRIE DPNKVHKLQ DPNKVHKLQ HPEKVHTLK	200 VIVLIRLGEKT VIVLIRLGEKT VIVLIRLGEKT VIVLIRLGEKT VIVLIRLGERT INVHIETGEPN INVHIETGEPN INVHIETGEPN INVHIETGEPN INVHIETGERS ANVHIETEGSS ANVHIETESSP	210 TEKCGAGSLLDI TEKCGAGSLLDI TERCGAGSLLDI TERCGAGSLLDI TERCGAGSLDI TERCGAGSLDI TERCGAGSLDI VESCEGGSWCTI VESCEGGSWCTI SUACSSSSLNET SUACSSSSLNET SUACSSSSLNET SUACSSSSLNET SUACSSSSLNET	220 EKL VKRKHF EKL VKRKHF EKVKRKF EKRLKDNGF EKRLKDNGF EDRLEALGF EDRLEALGF EDRLEALGF EDRLEALGF KMIVQKRNM KMIVQKRNM KSIVNKRNM	230 AFDCVENP GFDCVENP GFDCVENP QYSCINDY QYSCINDY QHSCINDY QHSCINDY IFACVDNY IFACVDNY IFACQDNY IFACQDNY	240 RAVLFLLCS RAVLFLLCS KSVLFLLCA RPVKLLQCV RPVKLLQCV RPVKFLHCV PPVKFLHCV PPVKFLHCV RPARFLQCV RPARFLQCV RPVRFLQCV	250 DNPNAREC DNPNAREC DNPNAREC DNSTHPDC DHSTHPDC DHSTHPDC DHSTHPDC CHSTHPDC KNPEHPSC KNPEHPSC KNPEHPSC	260
gi 1277941 sp1P292411 gi 124394271 sp1027312 gi 12554761 lpdb1118E1 gi 120150823651 gb1AH112 gi 120150823651 gb1AH112 gi 120532021ref1NP_03 gi 120830361 ref1NP_03 gi 120830361 ref1NP_03 gi 120830361 ref1NP_03 gi 120830361 ref1NP_03 gi 120830361 ref1NP_03 gi 1208403181 ref1NP_03 gi 1208403181 ref1NP_03	131 I CPYQAR TCPYQAR DCPNQAR DCPNPY DCENNPY DCENNPY DCENNAY DCENNAY NCPNNPI NCPNNPI NCPNNPI NCPNNPI NCPNNPI NCPNNPI	140 ESF HGHA ESF HGHA DSF HKRA DSF HKRA SVF HTV SVF HTV	150 SSSYAHSAEG SSSYAHSAEG SSSYAHSAEG SSSYAHSAEG SSSYAHSAEG SSSYAHSAEG SIQYSKDSSG SHQYSRDSG SH	160 EVTYHVDGSN EVTYHVDGSN DVTYHVDGSN DVTYHVDGSN VIHVHLNGSE VIHVHLNGSE VIHVHLNGSE VINVHLNGSE VINVHLNGSE VVQVHLNGSI VVQVHLNGSI VVQVHLNGSI TVYVHLNGSE	170 PKVPAYRPD PKVPAYRPD PKVPAYRPD PT-GAYPIK PT-GAYPIK PT-GAYPIK PK-GAYPTR PK-GAYPTR PK-GAYPTR PK-GAYPTR PK-GAYPTR SEPFYRN SEPFYRN SEPFYRN SEPFYRN SEPFYRN SEPFYRN SEPFYRN SEPFYRN SEPFYRN SEPFYRN SEPFYRN SEPFYRN SEPFYRN	180 FFFGKYELPNL FFGKYELPNL FFFGYELPNL FFFGYELPNL FFFGYELPNL FFFGFELPYL FFFGFELPYL FFFGFELPYL FFFGFELPYL FFFGSVEVFNL STFGSVEVFNL STFGSVEVFNL STFGSVEVFNL STFGSVEVFNL	190 -TNKVTRVK -TNKVTRVK -TNKVTRVK QKEKITRIE QKEKITRIE QKEKITRIE QKOKVTRIE QKOKVTRIE DPNKVHKLQ DPNKVHKLQ DPNKVHKLQ DPNKVHKLQ	200 VIVLHRLGEKI VIVLHRLGEKI VIVLHQLGQKI INVHHEIGGPN INVHHEIGGPN INVHHVOGPPN INVHHVOGPN INVHHVOGPN INVHHUDIGASS RNVHHVIIGIGASS	210 TEKCGAGSLLDI TEKCGAGSLLDI TERCGAGSLLDI VESCEGGSNKVI VESCEGGSNKVI VESCEGGSVKTI SNACSSSLNEI SNACSSSLNEI SNACSSSLNEI SNACSSSSLNEI SNACSSSSLNEI SNACSSSSLNEI SNACSSSSLNEI	220 EKL VKRKHF EKL VKRKHF ENV VKRKF EKRL KDNGF EKRL KDNGF EKRL KDNGF EDRL EALGF EDRL EALGF EDRL EALGF EDRL EALGF EDRL EALGF KNI VQKRNH KNI VQKRNH KSI VNKRNH KSI VNKRNH KSI VNKRNH	230 AFDCYEMP AFDCYEMP QYSCINDY QYSCINDY QYSCINDY QHSCINDY QHSCINDY USCINDY	240 RRVLFLLCS RAVLFLLCS KSVLFLLCA RPVKLLQCV RPVKLLQCV RPVKLLQCV RPVKFLHCV RPARFLQCV RPARFLQCV RPARFLQCV RPVRFLQCV RPVRFLQCV RPARFVQCV	250 DNPNARECI DNPNARECI DNSTHPDCI OHSTHPDCI OHSTHPDCI OHSTHPDCI VDHSTHPDCI VDHSTHPDCI KNPEHPSCI KNPEHPSCI RHPEHPSCI	260 260 200 200 200 200 200 200
: i 1277941 sp1P292411 gi 124394271 sp1027312 gi 124534761 pdb111.BE1+ gi 12554761 pdb111.BE1+ gi 120150423651 gb1AMH12 gi 12053051 pdb11574 gi 125405581 ref1NP_0 gi 125405581 ref1NP_1 gi 120803051 ref1NP_1 gi 126803051 ref1NP_1 gi 126803051 ref1NP_10 gi 12680751 ref1NP_0 gi 136467541 ref1NP_0 gi 136467541 ref1NP_0	131 I TCPYQAR TCPYQAR DCENNPY DCENNPY DCENNPY DCENNAY DCENNAY DCENNAY DCENNAY NCPNNPI NCPNNPI NCPNNPI NCSSTAT NCSSTAT	140 ESF HGHF ESF HGHF DSF HKRF DSF HKRF DSF HKRF DSY HKSF DAY HKSF DAY HKSF DAY HKVI SVF HTVV SVF HTVV SVF HTVV	150 150 1555 YHHSHEG 1555 YHHSHEG 1555 YHHSHEG 1510 YSKDSSG 1510 YSKDSSG 1510 YSKDSSG 1510 YSRDSSG 1540 YSRDSSG 1540 YSRDSSG 150K FAEDACG 150K FAEDACG 150K FAEDACG 150K FAESACG 150K F	160 EVTYHVDGSN EVTYHVDGSN UTYHVDGSN VIHVHLNGSE VIHVHLNGSE VIHVHLNGSE VIHVHLNGSE VINVHLNGSE VVQVHLNGSL VVQVHLNGSL VVQVHLNGSL VVQVHLNGSL TVYVHLNGSR TVYVHLNGSR	170 PKVPAYRPD PKVPAYRPD PKVPAYRPD PT-GAYPIK PT-GAYPIK PK-GAYPTR PK-GAYPTR PK-GAYPTR PK-GAYPTR SH-TFPYRN SN-TFPK SN-TFPK SN-TFPK	180 FFGKYELPNL FFGKYELPNL FFGMYELPNL FFGMYELPNL FFGMYEIPNL FFGMYEIPNL FFGMFEIPYL FFGMFEIPYL FFGMFEIPYL FFGSVEVFSL STFGSVEVFSL STFGSVEVFSL STFGSVEVFNL STFGSVEVFNL STFGSVEVFNL STFGSVEVFNL	190 -TNKYTRVK -TNKYTRVK -TNKYTRVK QKEKITRIE QKEKITRIE QKEKITRIE QKOKYTRIE QKOKYTRIE QKOKYTRIE DPNKVHKL DPNKVHKL DPNKVHKL DPNKVHKL MPCRVHTLH	200 VIVLIRLGEKI VIVLIRLGEKI VIVLIRLGEKI VIVLIRLGEKI INVHHEIGGPN INVHHEIGGPN INVHHOVGPN INVHHOVGPN INVHHOUGGPN INVHHOIEGSS ANVHHOIEGSS ANVHHOIGGERS	210 TEKCGAGSLLD TEKCGAGSLLD TERCGAGSLLD VESCGEGSNKVI VESCGEGSNKVI VESCGEGSNKVI VESCGEGSNKTI VESCGEGSVKTI SNACSSSLNEI SNACSSSSLNEI SNACSSSSLNEI SNACSSSSLNEI SNACSSSSLNEI SNACSSSSLNEI SNACSSSSLNEI SNACSSSSLNEI SNACSSSSLNEI SNACSSSSLNEI SNACSSSSLNEI	220 EKL VKRKHF EKL VKRKHF EKL KONGF EKRL KONGF EKRL KONGF EKRL KONGF EDRLEALGF EDRLEALGF EDRLEALGF EDRLEALGF KNIVQKRNM KSIVNKRNM KSIVNKRNM KSIVNQRNI KSIVNQRNI	230 FICYUNE AFDCYENE AF	240 RAVLFLLCS RAVLFLLCS RAVLFLLCS RAVLFLLCY RPVKLLQCV RPVKLLQCV RPVKFLHCV RPVKFLHCV RPARFLQCV RPARFLQCV RPARFLQCV RPARFVQCV RPARFVQCV RPARFVQCV	250 DNPNARECI DNPNARECI DNPNARECI DNSTHPDCI /DHSTHPDCI /DHSTHPDCI /DHSTHPDCI /KNPEHPSCI /KNPEHPSCI /KNPEHPSCI /KNPEHPSCI	260 260 RLAKRFYRIA RLAKRFYRIA RLAKRYRIA LKSRAAATO LKSRAATO LKSRAATO LKSRAATO LKSRAATO LKSRAATO LKSRAATO LKSRAATO LKSRAATO LKSRAATO LKSKAATO
gil277941splP22411 gil24934271splQ2731 gil24934271splQ2731 gil2547611pdb11LBEr gil201502831pdb11LST gil47578741ref1NP_00 gil208303541ref1NP_03 gil208303541ref1NP_13 gil63808821ref1NP_03 gil20830351ref1NP_13 gil63405181ref1NP_03 gil6404511ref1NP_00 gil64045181ref1NP_00 gil43026551ref1NP_00 gil43026551ref1NP_00 gil43026551ref1NP_00 gil43026551ref1NP_00 gil43026551ref1NP_00	131 I TCPYQAR TCPYQAR DCENNPY DCENNPY DCENNPY DCENNPY DCENNPY NCPNNPI NCPNNPI NCPNNPI NCSSTAT DCSNIPY DCSNIPY	140 ESF HGHP ESF HGHP ESF HGHP DSF HKRP DSF HKRP DSF HKRP DSF HKRP DSF HKRP DSF HKRP TVF HKVI TVF HKVI TVF HKVI SVF HTVV SVF HTVV SVF HTVV	150 SSSYAHSAEG SSSYAHSAEG SSSYAHSAEG SIQYSKDSSG SIQYSKDSSG SIQYSKDSSG SIQYSKDSSG SAGYSKDSSG SAGYSKDSSG SGKFAEDACG SGKFAEDACG SGKFAEDACG SGKFAESAC SGKFAESAC	160 EVTYHVDGSN EVTYHVDGSN DVTYHVDGSN DVTYHVDGSN UTWHLNGSE VIHVHLNGSE VIHVHLNGSE VINVHLNGSE VVQVHLNGSL VVQVHLNGSI TVYVHLNGST TVYVHLNGST TVYVHLNGST VVHVHLNGST	170 PKVPAYRPD PKVPAYRPD PKVPAYRPD PT-GAYPIK PT-GAYPIK PK-GAYPTK PK-GAYPTK REPFYKN SRFFYKN SNTFDEK TTAFSKA SKTFDKN	180 SFF GKYELPNL SFF GKYELPNL SFF GKYELPNL SFF ADYEIPNL SFF ADYEIPNL SFF ADFEIPYL SFF ADFEIPYL SFF ADFEIPYL SFF GSVEVFSL STF GSVEVFSL STF GSVEVFSL STF GSVEVFNL STF GSVEVFNL STF GSVEVFNL STF GSVEVFNL STF GSVEVFNL	190 -TNKVTRVK -TNKVTRVK -TNKVTRVK -TNKVTRVK QKEKITRIE QKOKVTRIE QKOKVTRIE QKOKVTRIE QKOKVTRIE DPNKVHKLQ DPNKVH	200 VIVLNRLGEKI VIVLNRLGEKI VIVLNRLGGKI INVNNEIGGPNI INVNNEIGGPNI INVNNEIGGPNI INVNNEGGPNI INVNNDIEGSN ANVNNDIEGSS ANVNNDIEGSS ANVNNDIEGSS ANVNNDIEGSS ANVNNDIEGSF ANVNNDIGGEFER	210 TEKCGAGSLLDI TEKCGAGSLLDI TERCGAGSLLDI VESCEGGSHKVI VESCEGGSHKVI VESCEGGSHKVI VESCEGGSVCII VESCEGGSVCII VESCEGSVSI NIACSSSSINEI SIACSSSSINEI SIACSSSSINEI SIACSSSSSINEI RISCLGSSIKEI RISCLGSSIKEI RISCLGSSIKEI RISCLGSSIKEI RISCLGSSIKEI	220 EKL VKRKHF EKL VKRKHF EKL KONGF EKRL KONGF EKRL KONGF EDRL EALGF EDRL EALGF EDRL EALGF KH VQKRNM KHI VQKRNM KSI VNRKNI KSI VNQRNI SSI TSKRNI ESI TSKRNI	230 AFDCVEMP AFDCVEMP QYSCINDY QYSCINDY QYSCINDY QYSCINDY QYSCINDY QYSCINDY QYSCINDY QYSCINDY QYSCINDY QYSCINDY QYSCINDY TFCQDY SFFCQDDY SFFCQDDY SFFCQDDY SFFCQDDY	240 RAVLFLLCS RAVLFLLCS RAVLFLLCS REVKLLQCV RPVKLLQCV RPVKFLHCV RPVKFLHCV RPARFLQCV RPARFLQCV RPARFLQCV RPARFLQCV RPARFVQCV RPARFVQCV RPARFVQCV RPARFVQCV	250 DINPINAREC DINPINAREC DINPINAREC DINFINPOL DINSTHPDC DINSTHPDC DINSTHPDC DINSTHPDC DINSTHPDC DINSTHPDC NUMETHERSC IKINPEHPSC IKINPEHPSC IKINPEHPSC IKINPEHPSC IKINPEHPSC IKINPEHPSC IKINPEHPSC IKINPEHPSC	260
gil277941splP292411 gil24934271splQ7312 gil2547611pdb11LBE1 gil2015042361gb1AH12 gil2015042361gb1AH12 gil75734021ref1NP_0 gil67534021ref1NP_1 gil208303611ref1XP_1 gil208303611ref1XP_1 gil6806821ref1NP_1 gil6806821ref1NP_0 gil208303611ref1XP_0 gil6807612ref1NP_0 gil208303611ref1XP_0 gil308030511ref1NP_0 gil3080741ref1XP_0 gil30805551ref1NP_0 gil30805551ref1NP_0 gil122634001splQ91c	131 I	140 ESF HGHF ESF HGHF DSF HKRF DSF HKRF DSF HKRF DSF HKRF DSF HKRF DSF HKRF DSF HKRF SVF HTV SVF HTV SVF HTV SVF HKTV SVF HKTV	150 SSSYAHSAEG SSSYAHSAEG SSSYAHSAEG SIQYSKDSSG SIQYSKDSSG SHQYSRDSSG SHQYSRDSSG SHQYSRDSSG SHQYSRDSSG SQKFAEDACG SQKFAEDACG SQKFAEDACG SQKFAESACG S	160 EVTYHVDGSN EVTYHVDGSN VIHVHLNGSE VIHVHLNGSE VIHVHLNGSE VIHVHLNGSE VIHVHLNGSE VINVHLNGSE VVQVHLNGSI TVYVHLNGST TVYVHLNGST TVYVHLNGSR TVYVHLNGSR TVYVHLNGSR TVYVHLNGSR VVHVHLNGSR VVHVHLNGSR VVHVHLNGSR	170 PRVPAYRPD PRVPAYRPD PT-GAYPIK PT-GAYPIK PT-GAYPIK PK-GAYPIK PK-GAYPTR PK-GAYPTR PK-GAYPTR PK-GAYPTR SEPFYRN SEPFYRN SITFDEK SITFDEK SKIFDKN SKIFDKN	180 SFFGKYELPNL SFFGKYELPNL SFFGYELPNL SFFGYELPNL SFFGYEIPNL SFFGDFEIPYL SFFGDFEIPYL SFFGDFEIPYL STFGSVEVFNL STFGSVEVFNL STFGSVEVFNL STFGSVEVFNL STFGSVEVFNL STFGSVEVFNL STFGSVEVFNL STFGSVEVFNL STFGSVEVFNL STFGSVEVFNL STFGSVEVFNL STFGSVEVFNL STFGSVEVFNL	190 	200 VIVU HRLGEKI VIVI HRLGEKI HVVI HRLGEKI HVVI HGLGKI HVVI HGLGKI HVVI HGGPN HVVI HGGPN HVVI HGGPN HVVI HGGRDSI HVVI HGGRDSI HVVI HGGRDSI HVVI HGGRDSI	210 TEKCGAGSLLDI TEKCGAGSLLDI TERCGAGSLLDI VESCEGGMIKVI VESCEGGMIKVI VESCEGGSVICI VESCEGGSVICI VESCEGGSVICI SUACSSSLNEI SUACSSSLNEI SUACSSSLNEI SUACSSSLNEI SUACSSSLNEI SUACSSSLNEI SUACSSSLNEI BUSCLGSSTIKEI RULCQOPTIKEI	220 EKL VKAKHF EKL VKAKHF EKL KANGF EKRL KDMGF EKRL KDMGF EDRL EALGF EDRL EALGF EDRL EALGF KMI VQKRNM KSI VNKRNM KSI VNKRNM KSI VNRNI KSI VNQRNI ESI ISKRNI ESI ISKRNI	230 AFDCVEMP AFDCVEMP QYSCINDY QYSCINDY QYSCINDY QYSCINDY QYSCINDY QHSCINDY QHSCINDY TFACQUNY TFACQUNY TFACQUNY TFACQUNY SFFCQDDY SFFCQDDY QFSCKNTY QFSCKNTY	240 RRYLFLLCS RRYLFLCS KSVLFLLCR RPVKLLQCV RPVKLLQCV RPVKLLQCV RPVKFLHCV RPVKFLHCV RPARFLQCV RPARFLQCV RPARFLQCV RPARFQCV R	250 DDNPNAREC DDNPNAREC DDNPNAREC DDNSTHPDC DDSTHPDC DDSTHPDC DDSTHPDC DDSTHPDC TOHSTHPDC TOHSTHPDC TOHSTHPDC TOHSTHPDC TKNPEHPSC KNPEHPSC KNPEHPSC KNPEDSSC KNPEDSSC	260

Figure 1. Conserved Structure

d3

The cyclase dimer is shown in a stereo diagram. Residues shown in red are highly conserved in a sequence alignment of ADP ribosyl cyclase, BST-1, and CD38. Disulfide bonds are shown in green, and they are also conserved. Sequences of various cyclase (cyc), BST-1 (bst), and CD38 (cd38) molecules are shown in a truncated aligned stack with highly conserved residues shown in red. It is clear that many conserved residues are clustered near the catalytic cleft of each monomer. The figure was rendered with the program PyMOL (http://pymol.sourceforge.net).

et al., 1996; Munshi et al., 1999) and to each other with C_{α} rms differences of about 1 Å or less, and somewhat similar to the recently solved structure of BST-1 (Yamamoto-Katayama et al., 2002) with a C_{α} rms difference of about 3.5 Å. With respect to these earlier structures, improvements in crystallographic resolution together with crucial differences of bound substrates are found in the current structures.

A careful delineation of the dimeric topology and subdomain structure of the cyclase monomer assists with the mechanistic interpretation of its enzyme activity. A structural overlay of sequence similarity data within the cyclase family (comprising cyclase, CD38, and BST-1) shows that conserved residues are clustered in the dimeric cavity, especially in the substrate binding clefts (Figure 1). This region of the protein corresponds to a region that we have called the "substrate handler," and it encompasses most of the individual residues which have been found to affect enzymatic activity. This handler is intermediate between two large subdomains at the N- and C termini of the protein (Figure 2), an α unit and an $\alpha\beta$ unit. The handler provides most of the binding surface for the bulky side chains of the substrate and so determines the relative specificity of the enzyme. Key residues of the handler are nestled deep in the dimeric cavity and cleft, and such an arrangement would impede proteolysis affecting enzymatic activity, and block nonspecific access to the hydrolyzing power of the active site.

Although the α and $\alpha\beta$ units are less conserved than the handler, those residues which are conserved are clustered in regions of dimer interaction or scaffolding for the handler unit. In addition, the loops of both the α and $\alpha\beta$ units contain conserved disulfide bonds, which hold the domains securely, and are likely to impede proteolysis of the exterior loops. Loops 1 and 2 of the α unit both have conserved regions, which provide crucial underpinning for the handler unit, while helices B and C are more divergent. With a deeply buried β strand, the $\alpha\beta$ unit provides extensive scaffolding, so that residues



Figure 2. Subdomain View of Cyclase with Schematic Representation

The cyclase dimer is shown in a ribbon diagram with key structural components colored blue to green to red to gray from the N to the C terminus. Within one of the two cyclase molecules in the symmetrical dimer, residues which appear to play a role in the enzymatic activity are shown in stick representation. A convenient schematic view shows the coloring scheme that we have used for cyclase subdomain structure in the current study.

Glu179 and Trp140 can be positioned precisely for catalysis (Figure 3). A C-terminal helix bridges the dimer tail with conserved interactions. Strikingly, R5P is largely buried in the core of the substrate binding groove and interacts with residues which are thought to be critical to the catalytic function



Figure 3. Cyclase Active Site with Bound Substrates, R5P, Pyridylcarbinol, and Nicotinamide

The three domains of ADP ribosyl cylcase are shown in ribbon representation and colored from N to C, blue, green, and red respectively. Key residues of the active site are shown in ball-and-stick representation, with the atoms colored as follows: C, yellow; N, blue; O, red; and P, violet. In the structure, R5P is covalently linked at the C3' atom of the ribose ring to a carboxylate O of E179. The BES, pyridylcarbinol (PYC, left) or nicotinamide (NCA1, right), makes contact with E98 and is bound to W140 in the catalytic cleft. At right, W111 forms a second nicotine amide site (NCA2), which may shunt nicotine amide away from the active site in the course of the ADPr cyclization reaction. Together with the absence of bound R5P in the active site of the native structure, the results of this study show how BES compounds block cyclization and hydrolysis of the covalent intermediate. The figure was rendered with the program Povscript (http://dipsy.biochem.med.umich.edu/ ~peisach/povscript) (see Kraulis, 1991).



Figure 4. Schematic Representation of Cyclase Ligands and Reaction Mechanism The interaction of cyclase residues with R5P-Glu179 and pyridylcarbinol (Pyc) are shown in a schematic representation (top). The figure was made with Ligplot (Wallace et al., 1995). The proposed reaction mechanism is also shown. The covalent intermediate in the current structure apparently accumulates when there is an excess of nicotinamide or pyridylcarbinol, which blocks the cyclization step.

of the enzyme. The sugar group interacts with the main chain amine of Trp77 and the phosphate interacts with the sidechain of S78, so that R5P is held away from the hydrophobic sidechain of Trp77. Moreover, the covalently linked Glu-R5P residue spans a helix comprising residues 173-180, which interacts with the sugar residue along its length, and the phosphate group forms two hydrogen bonds with the N terminus of the helix (Figure 4). Although it is likely that the formation of the C3' covalent bond to Glu179 results in the elimination of the 3' hydroxyl, it is visible in the map and included in the structure. The appearance of this hydroxyl group in the electron density is probably due to the presence of a C1' or C2' bound covalent intermediate at lower occupancy (see Structural Analysis section below), which could not be distinguished from the C3' bound intermediate observed in the current structure at the resolution of the data. Thus, it appears that the handler and $\alpha\beta$ unit structures of cyclase provide for precise geometric orientation of the substrate and catalytic residues.

Hydrolysis of Nicotinamide Mononucleotide

The finding of R5P covalently bound to Glu179 is unexpected, and the substrate was apparently copurified with the enzyme. Although this observation of R5P might be explained as disorder in the second phosphate and purine group of a bound NAD, it is also possible that R5P is derived from the hydrolysis of nicotinamide mononucleotide (NMN), which cannot undergo the cyclization reaction. The competence of cyclase to catalyze the hydrolysis of NMN was tested by HPLC analyses as shown in Figure 5. After incubation of NMN with the cyclase, a portion was indeed hydrolyzed to nicotinamide (Figure 5A). This was further confirmed by measuring the time course of release of R5P from NMN during the hydrolysis reaction as shown in Figure 5B. Cyclase is a multifunctional enzyme capable of using different substrates, NAD and NADP, to produce structurally distinct products, cADPR and NAADP, respectively (Aarhus, et al. 1995). It is thus not surprising that it can also catalyze the hydrolysis of NMN to R5P. Indeed, a similar hydrolysis reaction has been shown to be catalyzed by CD38 (Sauve and Schramm, 2002; Sauve et al., 2000), the mammalian homolog of the cyclase. The covalently bound R5P observed in the cyclase crystals thus represents the first and definitive evidence that this hydrolysis reaction occurs via a covalent intermediate.

Structural Analysis

A key feature of the pyridylcarbinol- and nicotinamidebound structures is the presence of R5P covalently bound to Glu179, the "catalytic residue" (Sauve et al., 2000). It may appear as puzzling that the covalent bond to Glu179 occurs at the C3' position of R5P, as the proposed reaction mechanism involves C1' (Figure 4). We propose that the existence of the C3'-Glu179 bond implies that covalent bond chemistry can also proceed with Glu179 at C2' and C1' (Figure 6); a possibility that finds support from analogous reactions in acetyl ADPR (Sauve et al., 2001). It is also notable that the electron density trails off near the phosphate group (Figure 7). Hydrolysis of the diphosphate bond of NAD would yield



Figure 5. Hydrolysis of NMN to R5P Catalyzed by Cyclase (A) NMN (0.1 mM) was incubated with the cyclase (1 µg/ml) at pH 5 (20 mM sodium acetate) for 3 hr at room temperature. Samples were analyzed by reversed phase HPLC on a C18 column. (B) The time course of the release of R5P was measured by stopping aliquots of the reaction mixture with equal volume of charcoal (2% in 20 mM Tris-base and 2 mM MgCl₂). The activated charcoal bound up the NMN but not the product, R5P. After centrifuging for 5 min in a microfuge, the supernatants containing R5P released by the hydrolysis reaction were recovered and treated with alkaline phosphatase (10 U/ml) for 1 hr at 37°C. The amount of phosphate liberated from R5P was measured using the standard Malachite Green assay for inorganic phosphate.

the observed R5P, a reaction which is probably unrelated to cyclization, but which might be expected to occur in the time required for crystallization. It remains unclear whether the trailing density results from a residual amount of nonhydrolyzed diphosphate, NMN, or flexibility in the second phosphate with resulting disorder in the purine group of a bound NAD molecule. The C3'-Glu179 bond probably results from an intramolecular rearrangement that occurs between the ribose ring and the carboxylate moiety, when cyclization is blocked by pyridylcarbinol-class BES. When the substrate is present and unblocked, cyclization proceeds via the elimination of the carboxylate oxygen of Glu179 at C1' of R5P, and the product is released. This is the end state observed in the crystals grown with NGD, where neither nicotinamide nor pyridylcabinol was added, and covalently bound R5P was not observed. (It should be noted that R5P binding was not observed in the Glu179Ala mutant structure either.) Overall, these results are consistent with the notion that cyclization proceeds through a covalently bound intermediate at Glu179. Moreover, these structures together show that the covalent intermediate can be captured using a BES, because BES



Figure 6. Two Proposed Mechanisms to Form 3' Intermediate

The observed 3' intermediate may be derived by at least two possible mechanisms, nonhydrolysis (blue) or hydrolysis (red). Hydrolysis is thought to occur at the 1' position, but it is likely that certain analogous reactions can occur at the 2' and 3' positions as shown in the pathway to the right. It is also plausible that the intermediate pathway is an internal rearrangement that occurs without hydrolysis, shown at left, which is supported by similar 2' and 3' substitutions that occur in AADPR (Sauve et al. 2001). It should be noted that the 1' hydroxyl is left in the up position via hydrolysis, but in the down position via internal rearrangement. From a mechanistic standpoint, this difference might clarify whether base exchange substrates block hvdrolysis versus product release. Unfortunately, hydroxyl groups did not refine well in either configuration, and we are not able to distinguish these two possibilities at the current resolution of the data.

appears to block cyclization, and the covalent intermediate was not observed in the absence of BES. This conclusion is congruent with the similar effect of mechanism-based inhibitors on CD38 (Sauve and Schramm, 2002). Thus, it is now clear that covalent intermediate catalysis occurs in the course of the cyclization and base exchange reactions in the active site of *Aplysia* cyclase.

Comparison of high-resolution structures together with identification of the cyclase mechanism leads to a profound understanding of the residues that participate in the global reaction, and helps to explain the biochemical differences in the cyclase enzyme family. Homologybased models of CD38 constructed using the 3D-PSSM program (Kelley et al., 2000) assisted with this comparison (Figure 8). Cyclase residue Glu98 is conserved in CD38, but it appears as serine or cysteine in BST-1, and this variable residue also appears to be involved in the

reaction (Graeff et al., 2001). In cyclase and in the CD38 model, the carboxylate group of Glu98 directly opposes C1' and C2' of the ribose ring with respect to Glu179 of the enzyme, and these moieties together form a geometric reaction plane (Figure 3). The Glu98 is a strong hydrogen bond acceptor because the charged group is mostly buried in the core of the enzyme beneath Trp77, and also geometrically stabilized by an internal salt bridge to His85. It is therefore likely that Glu98 provides stabilization for the hydrolysis reaction and for nicotinamide elimination at ribose C1' by Glu179. Glu98 is also part of the nicotinamide binding site in the current structure and in BST-1 as well (Yamamoto-Katayama et al., 2002). The pyridylcarbinol-bound structure shows the interaction of Glu98 with the amine group of the aromatic ring in a manner similar to nicotinamide. After nicotinamide release, the purine group of the substrate must take its place in the binding site in order for cyclization



Figure 7. Electron Density Map

Ribose-5-phoshate (R5P) is covalently bound to Glu179, so that the residue spans a critical helix of the cyclase enzyme. In addition, the ribose ring makes contact with a nearby tryptophan residue (Trp77). In the top two panels, the final 2Fo-Fc electron density map, 1 σ , was calculated with the the program CNS (Brünger et al., 1998). In the middle panel, pyridylcarbinol (Pyc) is shown bound to Trp140 and Glu98. In the lower panel, a simulated annealing Fo-Fc omit map (pink) was calculated with R5P, Pyc, and an adjacent water molecule deleted from the structure. The omit map is shown at 1.7 σ . The figure was rendered with the program PyMOL (http://pymol.sourceforge.net).

to occur. Glu98 and Trp140 probably position the purine group of the substrate for nucleophilic attack on C1' of the ribose ring, leading to elimination of the carboxylate oxygen of Glu179. Thus, Glu98 would promote cyclization of the substrate in a manner consistent with the formation of a covalent intermediate at Glu179 of the enzyme so long as the active site can be cleared of nicotinamide. (Similar arguments can be made in regard to residue Glu78 of BST-1, which would appear to block the phosphate interactions with the N terminus of the adjacent helix which are observed in cyclase and the CD38 model [Figure 8].) In this scheme, Glu 98 is a crucial residue for cyclization and nicotinamide binding specificity. The substitution of cysteine in place of glutamic acid at position 98, which appears in mouse BST-1, may lead to a loss of specificity for cyclization or nicotinamide binding with respect to other BST-1 and cyclase, and to hydrolysis of the substrate at C1' of the ribose ring.

Another feature of the enzyme which might affect cyclization is the presence of a second nicotinamide binding site adjacent to the catalytic cleft. The second nicotinamide molecule is bound to Trp111 of the enzyme in the original cyclase structure (Figure 3), and the occupancy of this nicotinamide site appears to be higher than that of the initially observed site at Trp140 (which also corresponds to the pyridylcarbinol site). In BST-1 and in the CD38 model, this site is blocked by V136 and 1133 respectively. It might be expected that a second nicotinamide site would assist cyclization and hydrolysis by shunting of nicotinamide out of the active site and clearing Trp140 for the binding of the purine group of



Figure 8. Comparison of Cyclase and BST-1 Structures and CD38 Model

The cyclase subunits are colored blue, green, and red, from the N- to C-terminal respectively, and the side chains are shown in ball-andstick representation with yellow carbon, blue nitrogen, red oxygen, and violet phosphorus. BST-1 is colored gray, and the BST-1-based CD38 model is colored pink. E78 of BST-1 conflicts with the phosphate group of R5P in the current structure, which may indicate an impeded tendency toward cyclization with respect to cyclase and CD38, both of which have a serine residue in this position. The CD38 model is more similar to cyclase than to BST-1 in the region of the cyclization cleft surrounding R5P (cyclase-based model not shown). In contrast, CD38 and BST-1 are similar in the region of the second nicotinamide site of cyclase in that W111 is blocked by I133 or V136 respectively. Thus, it appears that CD38 shares properties affecting cyclization with cyclase, but CD38 also shares properties affecting nicotinamide binding with BST-1. The proteins are shown in ribbon representations. Key residues appear as ball-and-stick, and the N-terminal loops are truncated at the first helix for clarity purposes. The figure was rendered with the program Raster3D (Merritt and Bacon, 1997).

the cyclization substrate. Thus, an analysis of the current structures predicts that CD38 would be similar to BST-1 in nicotinamide binding, but nicotinamide release at Trp140 would be similar to cyclase due to the presence of the crucial residue, Glu98.

Structural Comparison of Enzymatic Mechanisms for Cyclase, CD38, and BST-1

These high-resolution structures, combined with comparison to the structure of BST-1 (Yamamoto-Katayama et al., 2002) and to our CD38 model, have provided for a detailed understanding of the cyclization mechanism and a structural explanation of the relative enzymatic differences which supports the known biochemical properties of this crucial protein family. In particular, the differentiation of relative tendency toward cyclization versus hydrolysis and stabilization of the covalent intermediate can all be explained based on the structures and on specific sequence differences. Overall, the CD38 model shares one of two cyclization-promoting properties with cyclase: it has a strong hydrogen bond accepor (Glu98) near the active site but not a second nicotinamide site, so that CD38 is expected to have similar cyclization and hydrolysis chemistry to cylase, but different nicotinamide binding properties. In this mechanistic scheme, mouse BST-1 does not share either property with cyclase, so that the cyclization reaction is impaired with respect to both CD38 and cyclase. The identification of a BES trapped covalent intermediate implies that BES release may play a role in determining cyclization versus hydrolysis; it is unclear how BES binding to Trp140 blocks hydrolysis, such binding apparently blocks cyclization sterically.

A general reaction model for the protein family proceeds from the understanding of the enzymatic mechanism of cyclase, and future experiments can be proposed which will better explain the biochemical differences between cyclase, CD38, and BST-1. For example, nicotinamide binding properties can be assayed with tryptophan fluorescence experiments. General cyclization and hydrolysis inhibitors might target the innermost nicotinamide site which is shared by all the proteins in this family. ADP-ribosyl cyclase activity can presumably be modulated by agents designed to specifically target the second nicotinamide site, which may reduce cyclic product while leaving other cyclase activities unaffected. Moreover, the pursuit of CD38 and additional inhibitor-bound structures at higher resolutions may lead to improved reagents and mechanistic insights, which could be of therapeutic interest.

Experimental Procedures

Crystallization, Data Collection, and Molecular Replacement The preparation of triclinic nicotinamide-bound Aplysia ADP-ribosyl cyclase crystals with unit cell dimensions a = 60.4 Å, b = 75.3 Å, c = 138.1 Å, α = 88.2°, β = 89.2°, γ = 89.1°, and the details of data collection and molecular replacement solution were previously described (Munshi et al., 1999). Since that time, monoclinic cyclase crystals with unit cell dimensions a = 70.3 Å, b = 58.3 Å, c = 72.4 Å, $\beta = 100.7^{\circ}$ have been grown under conditions similar to the triclinic crystals and in the presence of the BES compounds, such as pyridylcarbinol, or in the presence of NGD. The monoclinic crystals were grown by seeding at 18°C from a mixture of 2 µl protein solution and 2 µl reservoir solution (0.1 M imidazole [pH 7.5] and 12%-24% PEG 4K). The partial specific volume (Matthews, 1968) was similar for both crystal forms (2.7 for triclinic, 2.5 for monoclinic), corresponding to eight and two molecules of 29 kDa per asymmetric unit respectively for the triclinic and monoclinic crystals. The monoclinic structures were solved by molecular replacement with the program AMoRe (Navaza, 1994), using the original cyclase structure (Prasad et al.l., 1996) as a search model, and the triclinic nicotinamidebound structure (Munshi et al., 1999) has been refined to finality. All data were collected at MacCHESS with $\lambda = 0.93$ Å on beamline stations A1 and F1 using a Quantum 4 CCD detector, and the statistics of data collection and unit cell parameters are shown in Table 1.

Structural Refinement and Quality

The crystallographic refinement, molecular modeling and building, and molecular graphics calculations were performed using an Apple dual-processor G4 minicluster running the GNU-Darwin Distribution (http://www.gnu-darwin.org/). After an initial round of maximum likelihood positional refinement and simulated annealing using the program CNS (Brünger et al., 1998), the R factor fell to levels indicating a correct solution (25.21%, 25.74%, 25.72%, and 26.96% for the pyridylcarbinol-bound, nicotinamide-bound, native, and mutant structures respectively). The various ligands were built into the resulting simulated annealing omit maps, and a regimen of maximum likelihood phase refinement was applied, followed by an automated refinement procedure using ARP/WARP (Lamzin and Wilson, 1993) combined with multicrystal and noncrystallographic symmetry averaging using the program DM (Cowtan, 1994). The program PyMOL (http://pymol.sourceforge.net) was used for crystallographic strucTable 1 Data Collection and Refinement Statistics

Data Collection Statistics ^a								
	Pyridylcarbinol		Nicotinamide ^b 33–2.4 (2.6–2.4)		Native 25-1.7 (1.8-1.7)		Mutant 20–2.0 (2.1–2.0	
Resolution range (Å)	24–2.0 (2.1–2.0) 9.0 (20.0) 99.5 (96.6) 3.4							
R _{svm} (%)			10.8 (31.0)	5.4 (28.0) 99.1 (99.1) 3.3		8.6 (25.5) 99.7 (98.6) 3.8	
Completeness (%)			88.0 (44.7)				
Redundancy			3.9					
Crystallographic Parameters								
	а	b	с	α	β	γ	Space Group	
Pyridylcarbinol	70.3 Å	58.3 Å	72.4Å	90°	100.7°	90 °	P21	
Nicotinamide ^b	60.4 Å	75.3 Å	138.1 Å	88.2°	89.2°	89.1°	P1	
Native	70.3 Å	58.3 Å	72.4Å	90°	100.8°	90 °	P21	
Mutant	70.3 Å	58.3 Å	72.4Å	90 °	100.7°	90 °	P21	
Crystallographic Refinement Statis	stics							
	Pyridylcar	binol	Nicotinam	nide⁵	Native		Mutant	
Number of reflections	38,943		57,197		61,981		35,252	
Sigma cutoff	none		none		none		none	
R factor (%)	tor (%) 21.20		24.39		20.77		22.94	
Free R factor (%)	25.18		26.94		23.79		26.13	
Monomers per asymmetric unit	2		8		2		2	
Ligands	R5P, pyridylcarbinol		R5P, nicotinamide		none		none	
Total number of waters	92		0		276		66	
Rms deviation from ideal								
Bond lengths (Å)	0.0179		0.0139		0.0185		0.0152	
Bond angles (°) 1.8143		1.6915		1.8650		1.727		

^b Munshi et al. (1999).

ture building. In the last step, the models were refined using CNS and display good stereochemistry as judged by the programs CNS and PROCHECK (Laskowski et al., 1993). The final refinement and stereochemical statistics are shown in Table 1.

The automated refinement procedure in combination with averaging produced striking improvements in the electron density map, so that ribose-5-phosphate was clearly identified in the catalytic groove of the pyridylcarbinol- and nicotinamide-bound enzymes (Figure 7), A large number of protomers were available for averaging: eight per asymmetric unit in the nicotinamide-bound structure and two per asymmetric unit in the monoclinic crystals. It appears that the sugar interacts with the catalytic groove adjacent to the nicotinamide site (Munshi et al., 1999). This observation is supported by the observation of reagent hydrolysis in ADP-ribosyl cyclase (Figure 5), and by the recently published BST-1 structures (Yamamoto-Katayama et al., 2002). C3' of the sugar forms a covalent linkage with Glu179, consistent with the observation that this residue participates in a covalent intermediate as part of the ADP-ribosylation and cyclization reaction in the homologous enzyme CD38 (Sauve and Schramm, 2002; Sauve et al., 2000). Moreover, residues Glu98 and His85 form an internal salt bridge near the active site, and may function as a hydrogen bond acceptor in the cyclization reaction.

The structure of cyclase crystals grown in the presence of NGD was determined to 1.7 Å resolution, which provides the most detailed view of the enzyme to date, although the active site showed no substrate density. Inactive cyclase mutant Glu179Ala was also determined to 2.0 Å resolution, and the structure was similar to that of the native protein, which would imply that Glu179 plays an enzymatic role, but not a structural role.

Acknowledgments

This work was supported by grants from the NIH to H.C.L. (GM6033) and MacCHESS (RR01646). The data were collected at the Cornell High Energy Synchrotron Source (CHESS), which is supported by the NSF and NIH National Institute of General Medical Sciences under award DMR 9713424.

Received: April 25, 2003 Revised: November 12, 2003 Accepted: November 13, 2003 Published: March 9, 2004

References

Aarhus, R., Graeff, R.M., Dickey, D.M., Walseth, T.F., and Lee, H.C. (1995). ADP-ribosyl cyclase and CD38 catalyze the synthesis of a calcium-mobilizing metabolite from NADP. J. Biol. Chem. 270, 30327–30333.

Brünger, A.T., Adams, P.D., Clore, G.M., Delano, W.L., Gros, P., Grosse-Kuntsleve, R.W., Jiang, J.-S., Kuszewski, J., Nilges, N., Pannu, N.S., et al. (1998). Crystallography and NMR system (CNS): a new software system for macromolecular structure determination. Acta Crystallogr. D Biol. Crystallogr. 54, 905–921.

Cowtan, K. (1994). "DM." An automated procedure for phase improvement by density modification. Joint CCP4 and ESF-EACBM Newsletter on Protein Crystallography *31*, 34–38.

Dong, C., Wang, J., Neame, P., and Cooper, M.D. (1994). The murine BP-3 gene encodes a relative of the CD38/NAD glycohydrolase family. Int. Immunol. 6, 1353–1360.

Graeff, R., Munshi, C., Aarhus, R., Johns, M., and Lee, H.C. (2001). A single residue at the active site of CD38 determines its NAD cyclizing and hydrolyzing activities. J. Biol. Chem. 276, 12169–12173.

Harada, N., Santos-Argumedo, L., Chang, R., Grimaldi, J.C., Lund, F.E., Brannan, C.I., Copeland, N.G., Jenkins, N.A., Heath, A.W., Parkhouse, R.M., et al. (1993). Expression cloning of a cDNA encoding a novel murine B cell activation marker. Homology to human CD38. J. Immunol. *151*, 3111–3118.

Itoh, M., Ishihara, K., Tomizawa, H., Tanaka, H., Kobune, Y., Ishikawa, J., Kaisho, T., and Hirano, T. (1994). Molecular cloning of murine BST-1 having homology with CD38 and *Aplysia* ADP-ribosyl cyclase. Biochem. Biophys. Res. Commun. 203, 1309–1317.

Jackson, D.G., and Bell, J.I. (1990). Isolation of a cDNA encoding

the human CD38 (T10) molecule, a cell surface glycoprotein with an unusual discontinuous pattern of expression during lymphocyte differentiation. J. Immunol. *144*, 2811–2815.

Kaisho, T., Ishikawa, J., Oritani, K., Inazawa, J., Tomizawa, H., Muraoka, O., Ochi, T., and Hirano, T. (1994). BST-1, a surface molecule of bone marrow stromal cell lines that facilitates pre-B-cell growth. Proc. Natl. Acad. Sci. USA *91*, 5325–5329.

Kelley, L.A., MacCallum, R.M., Sternberg, M.J. (2000) Enhanced genome annotation using structural profiles in the program 3D-PSSM. J. Mol. Biol. *299*, 499–520.

Koguma, T., Takasawa, S., Tohgo, A., Karasawa, T., Furuya, Y., Yonekura, H., and Okamoto, H. (1994). Cloning and characterization of cDNA encoding rat ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase (homologue to human CD38) from islets of Langerhans. Biochim. Biophys. Acta *1223*, 160–162.

Kraulis, P.J. (1991). MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures. J. Appl. Crystallogr. *24*, 946–950.

Lamzin, V.S., and Wilson, K.S. (1993). Automated refinement of protein models. Acta Crystallogr. D Biol. Crystallogr. *49*, 129–147.

Laskowski, R.A., MacArthur, M.W., Moss, D.S., and Thornton, J.M. (1993). PROCHECK: a program to check the stereochemical quality of structures. J. Appl. Crystallogr. *26*, 283–291.

Lee, H.C. (1991). Specific binding of cyclic ADP-ribose to calciumstoring microsomes from sea urchin eggs. J. Biol. Chem. 266, 2276– 2281.

Lee, H.C. (1996). Cyclic ADP-ribose and calcium signaling in eggs. Biol. Signals 5, 101–110.

Lee, H.C. (2001). Physiological functions of cyclic ADP-ribose and NAADP as calcium messengers. Annu. Rev. Pharmacol. Toxicol. *41*, 317–345.

Lee, H.C., Aarhus, R., and Walseth, T.F. (1993). Calcium mobilization by dual receptors during fertilization of sea urchin eggs. Science *261*, 352–355.

Lee, H.C., Aarhus, R., and Levitt, D. (1994). The crystal structure of cyclic ADP-ribose. Nat. Struct. Biol. *1*, 143–144.

Lee, H.C., Graeff, R., and Walseth, T.F. (1995). Cyclic ADP-ribose and its metabolic enzymes. Biochimie 77, 345–355.

Li, Q., Yamada, Y., Yasuda, K., Ihara, Y., Okamoto, Y., Kaisaki, P.J., Watanabe, R., Ikeda, H., Tsuda, K., and Seino, Y. (1994). A cloned rat CD38-homologous protein and its expression in pancreatic islets. Biochem. Biophys. Res. Commun. *202*, 629–636.

Matthews, B.W. (1968). Solvent content of protein crystals. J. Mol. Biol. 33, 491–497.

Merritt, E.A., and Bacon, D.J. (1997). Raster3D photorealistic molecular graphics. Methods Enzymol. 277, 505–524.

Munshi, C., Thiel, D.J., Mathews, I.I., Aarhus, R., Walseth, T.F., and Lee, H.C. (1999). Characterization of the active site of ADP-ribosyl cyclase. J. Biol. Chem. *274*, 30770–30777.

Navaza, J. (1994). AMoRe: an automated package for molecular replacement. Acta Crystallogr. A 50, 157–163.

Prasad, G.S., McRee, D.E., Stura, E.A., Levitt, D.G., Lee, H.C., and Stout, C.D. (1996). Crystal structure of *Aplysia* ADP-ribosyl cyclase, a homologue of the bifunctional ectozyme CD38. Nat. Struct. Biol. *3*, 957–964.

Sauve, A.A., and Schramm, V.L. (2002). Mechanism-based inhibitors of CD38: a mammalian cyclic ADP-ribose synthetase. Biochemistry *41*, 8455–8463.

Sauve, A.A., and Schramm, V.L. (2003). Sir2 regulation by nicotinamide results from switching between base exchange and deacetylation chemistry. Biochemistry 42, 9249–9256.

Sauve, A.A., Deng, H., Antelleti, R.H., and Schramm, V.L. (2000). A covalent intermediate in CD38 is responsible for ADP-ribosylation and cyclization reactions. J. Am. Chem. Soc. *122*, 7855–7860.

Sauve, A.A., Celic, I., Avalos, J., Deng, H., Boeke, J.D., and Schramm, V.L. (2001). Chemistry of gene silencing: the mechanism of NAD+dependent deacetylation reactions. Biochemistry *40*, 15456–15463. States, D.J., Walseth, T.F., and Lee, H.C. (1992). Similarities in amino acid sequences of *Aplysia* ADP-ribosyl cyclase and human lymphocyte antigen CD38. Trends Biochem. Sci. *17*, 495.

Wallace, A.C., Laskowski, R.A., and Thornton, J.M. (1995). LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng. 8, 127–134.

Willmott, N., Sethi, J.K., Walseth, T.F., Lee, H.C., White, A.M., and Galione, A. (1996). Nitric oxide-induced mobilization of intracellular calcium via the cyclic ADP-ribose signaling pathway. J. Biol. Chem. *27*, 3699–3705.

Yamamoto-Katayama, S., Ariyoshi, M., Ishihara, K., Hirano, T., Jingami, H., and Morikawa, K. (2002). Crystallographic studies on human BST-1/CD157 with ADP-ribosyl cyclase and NAD glycohydrolase activities. J. Mol. Biol. *316*, 711–723.

Accession Numbers

Protein structures have been deposited in the Protein Data Bank (accession codes: 1R16 [pyridylcarbinol], 1R15 [nicotinamide], 1R12 [native], and 1R0S [mutant]).